Ancestim
| Clinical data | |
|---|---|
| AHFS/Drugs.com | International Drug Names |
| Routes of administration |
s.c. injection only, premedication with H1 and H2 antihistamines and beta-receptor agonists for bronchodilation |
| Pharmacokinetic data | |
| Biological half-life | 2.5 h |
| Excretion | renal: 90% |
| Identifiers | |
| CAS Number | 163545-26-4  |
| ATC code | L03AA12 (WHO) |
| UNII | PYB4Q6JG41  |
| KEGG | D02937 |
| (what is this?) (verify) |
|
Ancestim is a recombinant methionyl human stem cell factor, branded by Amgen as StemGen. It was developed by Amgen and sold to Biovitrium, now Swedish Orphan Biovitrum, in December, 2008.[1]
It is a 166 amino acid protein produced by E. coli bacteria into which a gene has been inserted for soluble human stem cell factor.[2] It has a monomeric molecular weight of approximately 18,500 daltons and normally exists as a noncovalently associated dimer. The protein has an amino acid sequence that is identical to the natural sequence predicted from human DNA sequence analysis, except for the addition of an N-terminal methionine retained after expression in E. coli. Because Ancestim is produced in E. coli, it is nonglycosylated. Ancestim is supplied as a sterile, white, preservative-free, lyophilised powder for reconstitution and administration as a subcutaneous (SC) injection and is indicated for use in combination with filgrastim for mobilizing peripheral hematopoietic stem cells for later transplanation in certain cancer patients.[3]
References
- ↑ Amgen press office. Biovitrum Closes Product Acquisition Deal with Amgen
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Sobi's StemGen page]
<templatestyles src="Asbox/styles.css"></templatestyles>
 |
This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
